Moderna Therapeutics is a biotechnology company that researches and develops protein therapies based on novel messenger RNA (mRNA) technology. The company’s technology uses mRNA made of nucleotide analogs to trigger the body’s natural processes to produce proteins inside the human cell. This approach has the potential to produce therapeutic proteins in vivo to treat a wide range of diseases, including those that cannot be effectively treated with existing methods to develop and manufacture drugs. Moderna’s pipeline of mRNA product candidates covers a broad expanse of drug modalities, including vaccines (both for infectious diseases and personalized cancer vaccines), intracellular/transmembrane proteins, intratumoral expression, and secreted antibodies and proteins. Each modality represents a distinct approach to using the mRNA platform to encode proteins that achieve a therapeutic benefit, enabling the company to develop numerous drug candidates across a wide array of therapeutic areas. The company was founded in 2011 in Cambridge, Massachusetts through funding from Flagship Ventures. Moderna’s founders include Noubar Afeyan of Flagship Ventures, Kenneth R. Chien of Harvard University and the Karolinska Institutet, Robert S. Langer of the Massachusetts Institute of Technology and Derrick Rossi of Boston Children’s Hospital. Moderna is led by Stéphane Bancel, CEO and Director of the Board; Stephen Hoge, M.D., President; Marcello Damiani, Chief Digital Officer; Annie Seibold Drapeau, Chief Human Resources Officer, Steven W. Harbin, SVP, Manufacturing and Operations; Saqib Islam, Chief Business Officer; Jim R. Kasinger, J.D., General Counsel; Lorence Kim, M.D., CFO, and Tal Zaks, M.D., Ph.D., CMO.